A total of 14 studies were included to evaluate the impact of EGFR amplification on survival outcomes in glioblastoma patients [10,11,15,17,18,20,21,22,24,27,36,40,41,42], involving 580 patients with EGFR amplification (EGFR-amp) and 1032 patients with wildtype EGFR (EGFR-wt). The gene discussed is EGFR; the disease is glioblastoma.